FDA
-
-
-
-
-
-
-
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Me
-
-
-
-
-
-
-
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
-
-
-
-
-
-
-
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Local
-
-
-
-
-
-
-
FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-TAJS for extensive-stage small cell lung cancer
-
-
-
-
-
-
-
Jazz Pharmaceuticals receives FDA approval for brain tumor treatment
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Reports Zepzelca and Atezolizumab Combination Granted FDA Priority Review
-
-
-
-
-
-
-
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASC
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
